Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins

Bonora, Stefano; Mondo, Alessandra; Trentini, Laura; Calcagno, Andrea; Lucchini, A; Perri, Giovanni Di

doi:10.1016/j.jinf.2008.05.005

Cited by 14 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In selected patient populations (e.g. HIV and tuberculosis meningitis), MFX is a potential candidate to become part of the routine treatment [7,8].…”

Section: Introductionmentioning

confidence: 99%

Determination of moxifloxacin in dried blood spots using LC–MS/MS and the impact of the hematocrit and blood volume

Koster

Alffenaar

et al. 2011

Journal of Chromatography B

120

124

View full text Add to dashboard Cite

a b s t r a c tMoxifloxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance tuberculosis (MDR-TB). Due to variability in pharmacokinetics and in vitro susceptibility of causative bacteria, therapeutic drug monitoring (TDM) of MFX is recommended. Conventional plasma sampling for TDM is facing logistical challenges, especially in limited resource areas, and dried blood spots (DBS) sampling may offer a chance to overcome this problem. The objective of this study was to develop a LC-MS/MS method for determination of MFX in dried blood spots (DBS) that is applicable for TDM. The influence of paper type, the hematocrit (Hct) and the blood volume per spot (V b ) on the estimated blood volume in a disc (V est ) was investigated. The extracts of 8 mm diameter discs punched out from DBS were analyzed using liquid chromatography tandem mass spectrometry (LC-MS/MS) with cyanoimipramin as internal standard. The method was validated with respect to selectivity, linearity, accuracy, precision, sensitivity, recovery and stability. The effect of Hct and V b on LC-MS/MS analytical result was also investigated. The relationship between MFX concentrations in venous and finger prick DBS and those in plasma was clinically explored. V est was highly influenced by Hct while the effect of V b appeared to be different among paper types. Calibration curves were linear in the range of 0.05-6.00 mg/L with inter-day and intra-day precisions and biases of less than 11.1%. The recovery was 84.5, 85.1 and 92.6% in response to blood concentration of 0.15, 2.50 and 5.00 mg/L, respectively. A matrix effect of less than 11.9% was observed. MFX in DBS was stable for at least 4 weeks at room condition (temperature of 25 • C and humidity of 50%). A large range of Hct value produced a significant analytical bias and it can be corrected with resulting DBS size. A good correlation between DBS and plasma concentrations was observed and comparable results between venous DBS and finger prick DBS was attained. This fully validated method is suitable for determination of MFX in dried blood spot and applicable for TDM.

show abstract

“…In selected patient populations (e.g. HIV and tuberculosis meningitis), MFX is a potential candidate to become part of the routine treatment [7,8].…”

Section: Introductionmentioning

confidence: 99%

Determination of moxifloxacin in dried blood spots using LC–MS/MS and the impact of the hematocrit and blood volume

Koster

Alffenaar

et al. 2011

Journal of Chromatography B

120

124

View full text Add to dashboard Cite

show abstract

“…22 The clinical relevance of the findings of the present research is even greater given the most recent evidence concerning the possible use of fluoroquinolones for the treatment of tuberculosis. [23][24][25] This therapeutic option is important considering that mycobacterium tuberculosis causes disease from 0.35% to 15% of organ transplant recipients. 26 Unfortunately, for some fluoroquinolones, such as ciprofloxacin and levofloxacin, there are conflicting data concerning their possible influence on pharmacokinetics of CnIs.…”

Section: Discussionmentioning

confidence: 99%

Absence of Pharmacokinetic Interference of Moxifloxacin on Cyclosporine and Tacrolimus in Kidney Transplant Recipients

Capone

Tarantino

Polichetti

et al. 2010

The Journal of Clinical Pharma

View full text Add to dashboard Cite

This study investigates the potential pharmacokinetic interactions between an antimicrobial agent, moxifloxacin, and 2 immunosuppressant drugs, cyclosporine and tacrolimus, in kidney transplant recipients. Twenty-two kidney transplant patients needing antibiotic therapy for urinary tract infections are enrolled. Eleven patients are under cyclosporine treatment and the other 11 patients are under tacrolimus treatment. Because the urinary tract infections are caused by gram-negative aerobes sensitive to moxifloxacin, this antibiotic is administered by oral route at a dose of 400 mg/d for 1 week; in each patient pharmacokinetic studies are carried out before and at the seventh day of therapy. For both immunosuppressors, none of the pharmacokinetic parameters investigated show statistically significant differences between values obtained before and during treatment with moxifloxacin. In fact, the concentration-time profiles of monoclonal cyclosporine, polyclonal cyclosporine, and tacrolimus are not significantly different before and during the antimicrobial therapy. The results of the present study rule out interference of moxifloxacin with both cyclosporine and tacrolimus kinetics and indicate that the concomitant administration of the fluoroquinolone and cyclosporine or tacrolimus does not require modifications of the dosages of 2 immunosuppressant drugs.

show abstract

“…Aside from good tolerance, the lack of drug interactions proved to be advantageous.Random regimens could not be used. 35 Other serious intolerance to standard first-line anti-TB drugs is rare. Important examples include agranulocytosis 36 , thrombocytopenia 37 and renal failure.…”

Section: Newer Fqs For the Treatment Of Ds-tbmentioning

confidence: 99%

Untitled

Asif

2019

J. Med. Chem. Sci.

View full text Add to dashboard Cite

The fluoroquinolones-levofloxacin, moxifloxacin and gatifloxacin have potent bactericidal activities against Mycobacterium tuberculosis. They have the potential activity in managing both drug-susceptible and drug-resistant tuberculosis as well as the possibility of shortening the period of therapy. The emergence of drug-resistance, fluoroquinolone-resistant, multidrugresistant and extensively drug-resistant tuberculosis created a challenge to control the tuberculosis globally. The newer fluoroquinolones have clinical efficacy in some of the patients. So, the utility of newfluoroquinolone drugs for the treatment of tuberculosis is needed.

show abstract

Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins

Cited by 14 publications

References 18 publications

Determination of moxifloxacin in dried blood spots using LC–MS/MS and the impact of the hematocrit and blood volume

Determination of moxifloxacin in dried blood spots using LC–MS/MS and the impact of the hematocrit and blood volume

Absence of Pharmacokinetic Interference of Moxifloxacin on Cyclosporine and Tacrolimus in Kidney Transplant Recipients

Untitled

Contact Info

Product

Resources

About